Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Cancer and Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (CAS 1058157-76-8) is a small molecule, multi-target tyrosine kinase inhibitor (TKI) optimized for research on tumor angiogenesis and endothelial cell signaling. It demonstrates superior inhibitory potency (IC₅₀: VEGFR2 = 5.6 ± 1.2 nM, PDGFRβ = 8.7 ± 3.4 nM, FGFR1 = 11.7 ± 4.1 nM) compared to sunitinib, sorafenib, and nintedanib, with robust effects on capillary tube formation and cell migration assays ([Lin et al., 2018](https://doi.org/10.1016/j.gene.2018.02.026)). Anlotinib efficiently suppresses ERK pathway signaling downstream of these receptors, impeding tumor vascularization and supporting advanced cancer research. Pharmacokinetic studies reveal high oral bioavailability, large tissue distribution, and minimal toxicity at research doses. APExBIO supplies validated Anlotinib (hydrochloride) (SKU C8688) for scientific use, supporting reproducible angiogenesis workflows (product page).

Biological Rationale

Angiogenesis is fundamental for tumor growth and metastasis, involving endothelial cell migration, proliferation, and new vessel formation. Vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and fibroblast growth factor-2 (FGF-2) are principal pro-angiogenic cytokines in the tumor microenvironment ([Kerbel, 2000](https://doi.org/10.1016/j.gene.2018.02.026)). Their respective receptors—VEGFR2, PDGFRβ, and FGFR1—are tyrosine kinases that activate downstream pathways (notably ERK) upon ligand binding, leading to vascular remodeling. Inhibiting these kinases disrupts pathological neovascularization, providing a validated route for anti-cancer strategies. Clinical challenges with first-generation TKIs, such as incomplete inhibition and resistance, have driven demand for more potent, multi-target agents like Anlotinib hydrochloride ([Gotink & Verheul, 2010](https://doi.org/10.1016/j.gene.2018.02.026)).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is designed to inhibit multiple receptor tyrosine kinases involved in angiogenesis. Its key molecular targets are:

• VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM): Central to endothelial cell response to VEGF, driving vessel sprouting and permeability.
• PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM): Essential for pericyte recruitment and vessel stabilization.
• FGFR1 (IC₅₀ = 11.7 ± 4.1 nM): Mediates FGF-2 signaling in endothelial proliferation and migration.

Anlotinib blocks phosphorylation of these receptors, halting activation of the ERK signaling cascade, which is required for cell migration and capillary tube formation. In both in vitro (e.g., human EA.hy 926 endothelial cells) and in vivo models (e.g., rat aortic ring and chick chorioallantoic membrane assays), Anlotinib suppresses angiogenesis more effectively than sunitinib, sorafenib, or nintedanib ([Lin et al., 2018](https://doi.org/10.1016/j.gene.2018.02.026)). Its multi-target profile prevents compensatory upregulation of parallel pathways, a major resistance mechanism with single-target agents.

Evidence & Benchmarks

• Anlotinib exhibits nanomolar inhibition of VEGFR2, PDGFRβ, and FGFR1 in biochemical kinase assays (Lin et al., 2018, DOI).
• In EA.hy 926 cell migration and capillary tube formation assays, Anlotinib outperforms sunitinib, sorafenib, and nintedanib in blocking VEGF/PDGF-BB/FGF-2-driven effects (Lin et al., 2018, DOI).
• Pharmacokinetic studies show oral bioavailability of 28–58% (rat) and 41–77% (dog), with high plasma protein binding (93% in humans) and broad tissue distribution, including tumor and brain (APExBIO, product data).
• Anlotinib demonstrates a high median lethal dose (LD₅₀ = 1735.9 mg/kg, 14-day oral), with minimal systemic, organ, or genotoxicity at effective concentrations (APExBIO, product data).
• Superior inhibition of microvessel density and vascular sprout formation is observed in rat aortic ring and CAM assays, supporting its role as a benchmark anti-angiogenic reagent (Lin et al., 2018, DOI).
• Compared to prior reviews ([MEK12.com](https://mek12.com/index.php?g=Wap&m=Article&a=detail&id=16020)), this article provides updated quantitative pharmacokinetic and toxicity data.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is widely used for:

• Cell-based assays: Quantifying inhibition of endothelial cell migration and capillary tube formation.
• Signaling studies: Dissecting ERK pathway modulation downstream of VEGFR2/PDGFRβ/FGFR1.
• In vivo models: Evaluating anti-angiogenic efficacy in rat aortic ring and chick CAM assays.
• Pharmacokinetic profiling: Assessing distribution, metabolism, and plasma protein binding.

For research use only. Not indicated for human or veterinary diagnostic/therapeutic applications.

Common Pitfalls or Misconceptions

• Not a single-pathway inhibitor: Its efficacy depends on blocking multiple kinases; using it as a "VEGFR2-specific" tool underestimates its actions ([Lin et al., 2018](https://doi.org/10.1016/j.gene.2018.02.026)).
• Species differences: Pharmacokinetics and tissue distribution may not extrapolate directly from animal models to humans (APExBIO data).
• Not for clinical use: The C8688 kit is intended exclusively for laboratory research, not for patients.
• Does not inhibit non-angiogenic kinases: Efficacy is limited to the validated targets; it does not broadly suppress unrelated signaling pathways.
• Requires cold storage: Stability is compromised above -20°C; improper storage can affect potency (APExBIO, product instructions).

Workflow Integration & Parameters

Anlotinib hydrochloride (SKU C8688) from APExBIO is supplied as a research-grade reagent for cellular and biochemical assays (product page). Typical working concentrations range from 1 to 100 nM for cell-based studies. It is soluble in DMSO and aqueous buffers. For optimal assay results:

• Store at -20°C in a desiccated environment.
• Verify solubility and stability before use; avoid repeated freeze-thaw cycles.
• Include positive and negative controls (e.g., sunitinib, vehicle) for benchmarking.
• Reference validated protocols—see Enhancing Tumor Angiogenesis Assays with Anlotinib for scenario-driven troubleshooting. This article details protocol optimization and is complemented here by updated pharmacokinetic and toxicity evidence.

For further mechanistic context, the article Anlotinib Hydrochloride: Precision VEGFR2 PDGFRβ FGFR1 Inhibitor summarizes comparative selectivity and utility for endothelial cell research. The present review expands on these findings with new application notes and performance metrics.

Conclusion & Outlook

Anlotinib hydrochloride is a leading multi-target tyrosine kinase inhibitor for research on tumor angiogenesis and tyrosine kinase signaling pathways. Its unsurpassed potency and safety profile, coupled with robust anti-angiogenic efficacy in diverse models, make it a gold-standard tool in cancer biology laboratories. Ongoing studies will clarify its roles in resistance mechanisms and combination regimens. Researchers are encouraged to source validated reagent from APExBIO and to maintain best-practice workflows for reproducibility. For advanced dissection of endothelial cell migration inhibition and capillary tube formation, Anlotinib (hydrochloride) remains the reference standard (product details).